Delving into the Latest Updates on NF2105 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NF2105

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Philadelphia chromosome positive chronic myelogenous leukemia

Inactive Indication-

Originator Organization

Shenzhen Taili Biomedicine Co., Ltd.

Active Organization

Nycrist Pharmatech Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

（1）评价并比较健康受试者单次口服NF2105胶囊（空腹）与尼洛替尼胶囊（低脂改良空腹）的药代动力学特征；（2）评价健康受试者单次口服NF2105胶囊（空腹）与尼洛替尼胶囊（低脂改良空腹）的相对生物利用度；（3）评估健康受试者单次口服NF2105胶囊（空腹）及尼洛替尼胶囊（低脂改良空腹）的安全性。

[Translation]

(1) Evaluate and compare the pharmacokinetic characteristics of a single oral dose of NF2105 capsules (fasting) and nilotinib capsules (low-fat modified fasting) in healthy subjects; (2) Evaluate the relative bioavailability of a single oral dose of NF2105 capsules (fasting) and nilotinib capsules (low-fat modified fasting) in healthy subjects; (3) Assess the safety of a single oral dose of NF2105 capsules (fasting) and nilotinib capsules (low-fat modified fasting) in healthy subjects.

Start Date26 Mar 2026

Sponsor / Collaborator

Nycrist Pharmatech Ltd.

[+1]

CTR20255198

/ CompletedPhase 1

NF2105胶囊（112.5 mg）及尼洛替尼胶囊（300 mg）在健康受试者中的相对生物利用度研究

[Translation] Relative bioavailability study of NF2105 capsules (112.5 mg) and nilotinib capsules (300 mg) in healthy subjects.

（1）评价健康受试者单次空腹口服NF2105胶囊与尼洛替尼胶囊的相对生物利用度；（2）评价健康受试者单次空腹口服NF2105胶囊与尼洛替尼胶囊的药代动力学特征；（3）评估健康受试者单次空腹口服NF2105胶囊及尼洛替尼胶囊的安全性。

[Translation]

(1) To evaluate the relative bioavailability of NF2105 capsules and nilotinib capsules in healthy subjects after a single fasting oral administration; (2) To evaluate the pharmacokinetic characteristics of NF2105 capsules and nilotinib capsules in healthy subjects after a single fasting oral administration; (3) To assess the safety of NF2105 capsules and nilotinib capsules in healthy subjects after a single fasting oral administration.

Start Date08 Mar 2026

Sponsor / Collaborator

Nycrist Pharmatech Ltd.

[+1]

CTR20254486

/ CompletedPhase 1

NF2105胶囊及尼洛替尼胶囊在健康受试者中的药代动力学对比研究

[Translation] Comparative pharmacokinetic study of NF2105 capsules and nilotinib capsules in healthy subjects

（1）评价并比较健康受试者单次口服NF2105胶囊（空腹/餐后）、尼洛替尼胶囊（空腹/改良空腹）的药代动力学特征；（2）评价高脂饮食对健康受试者单次口服NF2105胶囊及尼洛替尼胶囊（改良空腹）药代动力学的影响；（3）评价健康受试者单次空腹口服NF2105胶囊与尼洛替尼原研胶囊的相对生物利用度；（4）评估健康受试者单次口服NF2105胶囊（空腹/餐后）及尼洛替尼胶囊（空腹/改良空腹）的安全性。

[Translation]

(1) Evaluate and compare the pharmacokinetic characteristics of single oral administration of NF2105 capsules (fasting/postprandial) and nilotinib capsules (fasting/modified fasting) in healthy subjects; (2) Evaluate the effect of a high-fat diet on the pharmacokinetics of single oral administration of NF2105 capsules and nilotinib capsules (modified fasting) in healthy subjects; (3) Evaluate the relative bioavailability of single oral administration of NF2105 capsules and the original nilotinib capsules in healthy subjects (fasting/postprandial); (4) Assess the safety of single oral administration of NF2105 capsules (fasting/postprandial) and nilotinib capsules (fasting/modified fasting) in healthy subjects.

Start Date25 Nov 2025

Sponsor / Collaborator

Nycrist Pharmatech Ltd.

[+1]

100 Clinical Results associated with NF2105

Login to view more data

100 Translational Medicine associated with NF2105

Login to view more data

100 Patents (Medical) associated with NF2105

Login to view more data

100 Deals associated with NF2105

Login to view more data